All products have special prices for bulk purchase, please contact for more details if required.

Cat. No.: FRCA-0.2 (for 10mM×0.2ml)

Cat. No.: FRCA-25 (for 25mg)

Cat. No.: FRCA-100 (for 100mg)

Description

Ferulic acid is a potent inhibitor of fibroblast growth factor receptor 1 (FGFR1), exhibiting IC50 values of 3.78 μM and 12.5 μM for FGFR1 and FGFR2, respectively.

Basic Information

• Aliases: Coniferic acid
• Source: Ligusticum chuanxiong hort
• Compound type: Phenylpropanoids > Cinnamic acid derivatives
• Chemical Formula: C10H10O4
• Molecular Weight: 194.18
• CAS Number: 1135-24-6
• Purity: 98%, HPLC
• Solvent/Solubility: DMSO: 100mg/ml (514.99 mM)
• Solution Preparation: Dissolve 2mg in 1.03ml DMSO, or 1.94mg in 1ml DMSO to prepare a 10mM solution.

Signaling Pathway

PI3K/Akt

In Vitro Study

Ferulic acid (FA) is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively. Ferulic acid exhibits great inhibitory activity on FGFR1 with an inhibitory rate of 92% at 1 µM. The proliferation of HUVEC stimulated by FGF1 is markedly decreased after Ferulic acid treatment ranging from 5 to 40 μM for 24 h. Ferulic acid does not exert significant cell viability up to 20 μM, but over 30 μM Ferulic acid exhibits a cytotoxic effect in HUVEC compare to the control. Ferulic acid inhibits FGF1-induced HUVEC migration and invasion in a dose-dependent manner. Ferulic acid markedly suppresses the FGF1-induced phosphorylation of PI3K and Akt. Ferulic acid treatments significantly inhibit MMP-2 and MMP-9 expression stimulated by FGF1.

In Vivo Study

Treatment with Ferulic acid (FA) potently inhibits FGF1-induced neovascularization. It is found that intragastric administration of Ferulic acid markedly inhibits tumor volume and tumor weight, as compare to the counterparts treated with DMSO. Furthermore, Ferulic acid treatment is well tolerated, and there is no significant difference in weight between the vehicle group and the FA-treated groups. Ferulic acid (0.01, 0.1, 1 or 10 mg/kg) given by oral route decreases significantly the immobility time in the forced swimming test (FST) and tail suspension test (TST), whereas produces no effect in the open-field test. Results demonstrate that the administration of Ferulic acid (0.001 mg/kg, p.o.) boosts the antidepressant-like effect of fluoxetine (5mg/kg, p.o.) in the TST.

Clinical Trial

NCT00777543: Healthy Males, Not Applicable.

Storage

Store at -20°C for at least one year. The solid powder is stable at 4°C for at least one month. If dissolved in a non-DMSO solvent, it is recommended to aliquot and store at -80°C for up to six months.

Precautions

• This product may have a certain degree of toxicity to the human body. Please take appropriate precautions to avoid direct contact with the body or inhalation.
• This product is for scientific research use only by professionals and is not intended for clinical diagnosis or treatment, food, or pharmaceutical purposes. It should not be stored in ordinary residential areas.
• For your safety and health, please wear laboratory attire and disposable gloves while handling.

Only for research and not intended for treatment of humans or animals

Journals Using SBS Genetech Products                                       Universities Using SBS Genetech Products

SBS Genetech is a long-term sponsor of Cold Spring Harbor Laboratory